Getinge’s Q2 16 performance, although a significant improvement over the disastrous first quarter, continued to be tepid, with the company under-delivering on all counters against consensus expectations (c.3% and c.43% miss on top-line and bottom-line, respectively). Q2 16 sales were down 0.3% yoy to SEK6.9bn, mainly due to the continued weakness in the Patient & Post-Acute Care segment (erstwhile Extended Care); this, despite a resilient performance by Acute Care and a trend revers
25 Jul 2016
Q2 16 offers little respite
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q2 16 offers little respite
Getinge AB Class B (GTN:FRA) | 0 0 0.9% | Mkt Cap: 25,911m
- Published:
25 Jul 2016 -
Author:
Jyoti Prakash -
Pages:
3
Getinge’s Q2 16 performance, although a significant improvement over the disastrous first quarter, continued to be tepid, with the company under-delivering on all counters against consensus expectations (c.3% and c.43% miss on top-line and bottom-line, respectively). Q2 16 sales were down 0.3% yoy to SEK6.9bn, mainly due to the continued weakness in the Patient & Post-Acute Care segment (erstwhile Extended Care); this, despite a resilient performance by Acute Care and a trend revers